MARKET

AGEN

AGEN

Agenus
NASDAQ
7.02
-0.13
-1.82%
Closed 19:30 11/10 EST
OPEN
7.10
PREV CLOSE
7.15
HIGH
7.13
LOW
6.64
VOLUME
691.63K
TURNOVER
0
52 WEEK HIGH
10.31
52 WEEK LOW
2.710
MARKET CAP
317.63M
P/E (TTM)
9.63
1D
5D
1M
3M
1Y
5Y
1D
Agenus price target raised to $16 from $14 at B. Riley
TipRanks · 1d ago
Agenus Price Target Raised to $16.00/Share From $14.00 by B. Riley Securities
Dow Jones · 1d ago
B. Riley Securities Reiterates Buy on Agenus, Raises Price Target to $16
Benzinga · 1d ago
Weekly Report: what happened at AGEN last week (1102-1106)?
Weekly Report · 2d ago
Agenus Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Simply Wall St · 2d ago
Agenus Announces New Findings From Long-Term Survivor Analysis Of Phase 1b C-800-01 Trial Evaluating Botensilimab In Combination With Balstilimab In Heavily Pretreated Patients With MSS, mCRC Without Active Liver Metastases
Benzinga · 4d ago
Agenus Inc. Reports Third Quarter 2026 Total Revenue of $31.5 million
NASDAQ · 5d ago
Agenus: Q3 Earnings Snapshot
Barchart · 5d ago
More
About AGEN
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.